Models Constructed to Predict Decline Over Time in MCI, Mild Dementia
Medically reviewed by Drugs.com.
By Elana Gotkine HealthDay Reporter
WEDNESDAY, July 10, 2024 -- Models can be constructed that predict cognitive decline using Mini-Mental State Examination (MMSE) scores over time for mild cognitive impairment (MCI) and mild dementia, according to a study published online July 10 in Neurology.
Pieter J. van der Veere, M.D., from the VU University Medical Center in Amsterdam, and colleagues constructed clinically applicable prediction models of cognitive dementia in amyloid-positive patients with MCI or mild dementia from the Amsterdam Dementia Cohort. Linear mixed modeling was used to predict the MMSE over time.
Data were included for 961 participants: 310 had MCI and 651 had mild dementia with 4 ± 2 MMSE measurements over two years. The researchers found that over time, there were increases in cognitive decline rates for both MCI and mild dementia. Backward selection retained age, sex, cerebrospinal fluid (CSF) β-amyloid (Aβ)1-42, and pTau as time-varying effects altering the MMSE trajectory for MCI. Time-varying effects of Aβ1-42, age, APOE ε4, and baseline MMSE were retained for mild dementia. In internal cross-validation, R2 was 0.15 and 0.26 for the MCI and mild dementia models, respectively. For a hypothetical patient with MCI, a baseline MMSE of 28, and CSF Aβ1-42 of 925 pg/mL, an MMSE of 20 was predicted after 6.0 years and after 8.6 years with a hypothetical treatment.
"There is a need among patients and care partners for prognostic information on their cognitive trajectory," the authors write. "These models can provide such information, although our results also emphasize that the heterogeneity in cognitive trajectories can only be partially captured."
Several authors disclosed ties to the biopharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
Source: HealthDay
Posted : 2024-07-11 07:15
Read more
- UroGen Announces FDA Acceptance of its New Drug Application for UGN-102
- Overtreatment of Prostate Cancer Increasing in Men With Short Life Expectancy
- Obesity-Linked Heart Deaths Nearly Tripled in U.S. Over Past Two Decades
- Telling Your Doctor About a Health Issue Doesn't Mean It Enters Medical Record
- Travel Time to Tanning Facilities Negatively Linked to Melanoma Incidence
- AHA: Half of U.S. Adults Are Eligible for Treatment With Semaglutide
Disclaimer
Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Popular Keywords
- metformin obat apa
- alahan panjang
- glimepiride obat apa
- takikardia adalah
- erau ernie
- pradiabetes
- besar88
- atrofi adalah
- kutu anjing
- trakeostomi
- mayzent pi
- enbrel auto injector not working
- enbrel interactions
- lenvima life expectancy
- leqvio pi
- what is lenvima
- lenvima pi
- empagliflozin-linagliptin
- encourage foundation for enbrel
- qulipta drug interactions